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(PPAR)-c and PPARa have shown neuroprotective eﬀects
in models of Parkinson’s disease (PD). The role of the third,
more ubiquitous isoform PPARd has not been fully explored.
This study investigated the role of PPARd in PD using 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to model
the dopaminergic neurodegeneration of PD. In vitro admin-
istration of the PPARd antagonist GSK0660 (1 lM) increased
the detrimental eﬀect of 1-methyl-4-phenylpyridinium iodide
(MPP+) on cell viability, which was reversed by co-treatment
with agonist GW0742 (1 lM). GW0742 alone did not aﬀect
MPP+ toxicity. PPARd was expressed in the nucleus of
dopaminergic neurons and in astrocytes. Striatal PPARd lev-
els were increased (over two-fold) immediately after MPTP
treatment (30 mg/kg for 5 consecutive days) compared to
saline-treated mice. PPARd heterozygous mice were not pro-
tected against MPTP toxicity. Intra-striatal infusion of
GW0742 (84 lg/day) reduced the MPTP-induced loss of
dopaminergic neurons (5036 ± 195) when compared to
vehicle-infused mice (3953 ± 460). These results indicate
that agonism of PPARd provides protection against MPTP
toxicity, in agreement with the eﬀects of other PPAR ago-
nists.
 2013 IBRO. Published by Elsevier Ltd.
Key words: MPP+, neurodegeneration, neuroinﬂammation,
SH-SY5Y, MPTP, PPAR delta.
Open access under CC BY license.0306-4522/13  2013 IBRO. Published by Elsevier Ltd.
http://dx.doi.org/10.1016/j.neuroscience.2013.02.058
*Corresponding author. Address: Institute of Medical Sciences,
Foresterhill, University of Aberdeen, Aberdeen, AB25 2ZD, United
Kingdom. Tel: +44-(0)-1224-437325; fax: +44-(0)-1224-437465.
E-mail address: p.teismann@abdn.ac.uk (P. Teismann).
 These authors contributed equally to this work.
Abbreviations: DMEM, Dulbecco’s Modiﬁed Eagle Medium; DMSO,
dimethyl sulfoxide; DPBS, Dulbecco’s phosphate-buﬀered saline;
EDTA, ethylenediaminetetraacetic acid; FCS, foetal calf serum;
GFAP, glial ﬁbrillary acid protein; IL, interleukin; LDH, lactate
dehydrogenase; MAC-1, macrophage antigen complex-1; MPP+, 1-
methyl-4-phenylpyridinium iodide; MPTP, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; MTT, 3-(4,5-dimethylthizol-2-yl)-2,5-
diphenyltetrazolium bromide; PBS, phosphate-buﬀered saline; PD,
Parkinson’s disease; PFA, paraformaldehyde; PPAR, peroxisome
proliferator-activated receptor; TH, tyrosine hydroxylase; TNFa,
tumour necrosis factor-a.
191
Open access under CC BY lINTRODUCTION
Parkinson’s disease (PD) is a common neurodegenera-
tive disease (Dauer and Przedborski, 2003). Its primary
neuropathogical feature is the loss of dopaminergic
nigrostriatal neurons, which results in the disabling
motor abnormalities that characterise PD: rigidity,
bradykinesia, resting tremor and postural instability
(Dauer and Przedborski, 2003). The pathogenesis of PD
is poorly understood, but amongst the processes
implicated in the degeneration of the dopaminergic
neurons is inﬂammation, as evidenced by the activated
glial cells and the upregulation of pro-inﬂammatory
cytokines seen in both models of PD and PD patients
(Czlonkowska et al., 1996; He´bert et al., 2003 McGeer
et al., 1988; Mogi et al., 1994a,b).
Peroxisome proliferator-activated receptors (PPARs)
are ligand-activated transcription factors with roles in
fatty acid and carbohydrate metabolism (Desvergne and
Wahli, 1999). There are three PPAR isoforms – a, c
and d (also known as b), each with varying tissue
distributions and ligand aﬃnities (Desvergne and Wahli,
1999). In addition, PPARs have been shown to regulate
inﬂammatory processes (Devchand et al., 1996; Ricote
et al., 1999; Delerive et al., 2001). To date, the
majority of the studies on the role of PPARs in
neurodegenerative diseases have focussed on PPARc,
as it is known to be a negative regulator of macrophage,
microglia and astrocyte function (Ricote et al., 1999;
Storer et al., 2005; Xu et al., 2005, 2006). Indeed
PPARc agonists show neuroprotective eﬀects in the 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
model of PD, with amelioration of MPTP-induced
dopaminergic neuron loss and reduced gliosis (Breidert
et al., 2002; Dehmer et al., 2004; Schintu et al., 2009;
Martin et al., 2012). Similar neuroprotective eﬀects have
also been seen with the PPARa agonist fenoﬁbrate
(Kreisler et al., 2007).
In contrast to PPARa and PPARc, less is known about
the roles of the more ubiquitous PPARd isoform, although
the receptor is thought to have a function in inﬂammation
control. Although these roles are less well understood,
the general trend is towards anti-inﬂammatory action as
PPARd activation, like that of PPARc, can inhibit the
production of pro-inﬂammatory cytokines, such as tumour
necrosis factor-a (TNFa), interleukin (IL)-1b and IL-6
(Bishop-Bailey and Bystrom, 2009). PPARd can also
control the inﬂammatory status of monocytes/macro-
phages (Bishop-Bailey and Bystrom, 2009). Indeed,icense.
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Alzheimer’s disease and multiple sclerosis, which are
concurrent with reduced glial cell activation (Niino et al.,
2001; Escribano et al., 2009). This suggests that PPARd
activation could provide neuroprotection in PD.
Furthermore, Iwashita et al. (2007) have shown that
PPARd agonists provide a degree of neuroprotection
against both cerebral infarcts and MPTP, although the
eﬀects were not fully explored. Consequently, this study
seeks to address the role of PPARd in MPTP toxicity by
using both an in vivo MPTP mouse model of PD and an
in vitro model using 1-methyl-4-phenylpyridinium iodide
(MPP+), the active metabolite of MPTP, in combination
with the PPARd agonist GW0742 and the PPARd
antagonist GSK0660.EXPERIMENTAL PROCEDURES
Chemicals
GW0742 and GSK0660 were a kind gift of GlaxoSmithKline
(Stevenage, UK). MPTP and MPP+ iodide were from Sigma–
Aldrich, Poole, UK. All other chemicals unless otherwise stated
were of analytical grade.Cell culture
Human neuroblastoma SH-SY5Y cells were cultured in
Dulbecco’s Modiﬁed Eagle Medium (DMEM; Sigma–Aldrich)
supplemented with 10% foetal calf serum (FCS; Biosera,
Ringmer, East Sussex, UK) and 100 units/ml penicllin/
streptomycin/glutamine (Invitrogen, Paisley, UK). Cells were
kept at 37 C in humidiﬁed 5% carbon dioxide and 95% air.
Cells were seeded at 6000 cells/well in 96-well plates. All
experiments were carried out 48 h after seeding and in serum-
free media. GW0742 and GSK0660 were dissolved in dimethyl
sulfoxide (DMSO) to make 1 mM solutions that were
subsequently diluted with Dulbecco’s phosphate-buﬀered saline
(DPBS; Sigma–Aldrich) and DMEM supplemented with
100 units/ml penicillin/streptomycin for experimental use. Final
solutions contained 0.1% DMSO. MPP+ was dissolved in
serum-free media and used at a ﬁnal concentration of 1.5 lM.
In experiments where GW0742 or GSK0660 was used together
with MPP+, cells were pretreated with GW0742 or GSK0660
for 16 h before the addition of MPP+. In co-treatment
experiments, cells were pretreated with GW0742 or GSK0660
as described above and the co-treatment was added at the
same time as MPP+.
Mesencephalic dissociated neurons were prepared from the
ventral mesencephalon of E14 rat (Sprague–Dawley) foetus as
previously (Hsieh et al., 2011). Experimental protocols were in
accordance with Home Oﬃce and institutional guidelines. The
ventral mesencephalons from 15 embryos were collected in
calcium- and magnesium-free Hank’s balanced salt solution
(Invitrogen) containing 5 mM sodium bicarbonate (pH 7.0–7.2).
Cells were dissociated with 0.25% trypsin in Hank’s balanced
salt solution. Dissociation was stopped by the addition of an
equal volume of foetal calf serum and 1 mg/ml DNAse (Roche).
Thereafter, tissue was triturated three times with a wide pore,
siliconised Pasteur pipette. Cells were plated on polyornithine
and laminin-coated coverslips at a density of 2.5  105 cells/
cm2 in 24-well plates. Culture medium consisting of Dulbecco’s
modiﬁed eagle medium with F12 nutrient mixture (Sigma) plus
1% N1 mix (Sigma), 10% FCS, 2 mM L-glutamine, 100 units/ml
penicillin/streptomycin (Invitrogen), and 1 lg/ml insulin (Sigma)
was supplied at 1000 ll/well.Cells were maintained at 37 C, 5% CO2 for 6 days. The
culture medium was changed after 24 h and then changed
every second day. Treatment was performed as described
above with a ﬁnal MPP+ concentration of 20 lM.Measurement of cell viability
Cell viability was determined by the conversion of the tetrazolium
salt, 3-(4,5-dimethylthizol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT; Invitrogen) to its insoluble formazan. After treatment,
10 ll of MTT solution (5 mg/ml) was added to the plated
cells and incubated at 37 C for 4 h. Media were then removed
and the formazan solubilised in 100 ll DMSO. The absorption
of the resulting solution was measured at 570 nm with
reference at 670 nm using a PowerWave XS microplate
spectrophotometer (Bio-Tek, Potton, Bedfordshire, UK).Measurement of lactate dehydrogenase release
Release of lactate dehydrogenase (LDH) into the culture media
from cells with damaged membranes was measured using an
assay kit (Cayman Chemicals, Ann Arbor, MI) as per the
manufacturer’s instructions.Apoptosis assay
The apoptosis assay was performed as described before (Hsieh
et al., 2011). Apoptosis was detected by Hoechst 33258 staining
(Molecular Probes). After immunocytochemistry staining, cells
were incubated for 20 min with Hoechst 33258 (2 lg/ml).
Healthy cells were identiﬁed by their evenly and uniformly
stained nuclei. Apoptotic cells showed cell nuclear
condensation and/or fragmentation. Apoptotic nuclei were
counted as a percentage of total tyrosine hydroxylase (TH)-
positive staining cells.Immunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde for 15 min. Cells were
extensively washed with phosphate-buﬀered saline (PBS)
between each step. Cells were permeabilised for 10 min in PBS
containing 0.1% Triton-X (PBS-T). Unspeciﬁc binding was
blocked with 10% normal goat serum (Vector Laboratories,
Peterborough, UK) in PBS-T containing 0.3 M glycine. Cells
were ﬁrst incubated in primary antibodies [mouse tyrosine
hydroxylase (1:200; Millipore, Watford, UK), PPARd (1:100),
Chemicon, Temecula, CA)] overnight at 4 C before incubation
in 1% normal goat serum in PBS-T with secondary antibodies
[goat anti-mouse Cy3 (1:200; Jackson ImmunoResearch, West
Grove, PA)] for 1 h at room temperature.
The coverslips were mounted, sealed and imaged by
ﬂuorescent microscopy at the same setting (LSM700, Carl
Zeiss, Hertfordshire, UK).Animals and drug treatments
All procedures were in accordance with the Animals (Scientiﬁc
Procedures) Act 1986 and MPTP handling and safety
measures were consistent with Jackson-Lewis and Przedborski
(2007). Twelve-week-old male C57BL/6 mice and PPARd wild-
type or heterozygote mice (previously described in Barak et al.,
2002) received intraperitonal injections of MPTP–HCl (30 mg/kg
free base) dissolved in saline, one injection for ﬁve consecutive
days, and were sacriﬁced by decapitation at selected times
ranging from 0 to 21 days after the last injection (3–7 mice per
timepoint). Control mice received saline only.
H. L. Martin et al. / Neuroscience 240 (2013) 191–203 193GW0742 was dissolved in N,N-dimethylformamide (DMF;
Fisher Scientiﬁc) and diluted with 0.1 M PBS. GW0742 does
not readily cross the blood–brain barrier so for treatment with
GW0742 intra-striatal infusion was used. Mice were
anaesthetised with 120 mg/kg ketamine and 16 mg/kg xylazine.
Once under anaesthesia, an L-shaped cannula was implanted
into the right striatum at the following coordinates: 0.5 mm
anterior to the bregma, 2 mm lateral to the midsagittal suture
and 3 mm ventral to the skull. The cannula was connected to
an Alzet osmotic pump (2002 model, Charles River, Margate,
UK) to infuse either GW0742 or vehicle (25% DMF in 0.1 M
PBS). Infusion rate was 0.5 ll/hour giving a total of 84 lg/day
for 48 h prior to, throughout MPTP treatment (25 mg/kg free
base for 5 consecutive days) and for 7 days afterwards.
Analgesia (0.1 mg/kg buprenorphine) was given before surgery
and on the day after surgery if necessary. Mice were sacriﬁced
21 days after the last MPTP injection and the implanted
striatum dissected out and snap frozen on solid carbon dioxide.
The remaining brain tissue was placed in 4% paraformaldehyde
(PFA).Human samples
Human samples were obtained from the UK Parkinson’s Disease
Society Tissue Bank at Imperial College, London. Selected PD
and control samples were matched for age at death and
interval from death to tissue processing. All procedures were
approved by the responsible ethics committee (North of
Scotland Research Ethics Committees).PPARd, TH, glial ﬁbrillary acid protein (GFAP),
macrophage antigen complex-1 (MAC-1) and NeuN
immunohistochemistry
This was performed as described in Teismann et al., 2003.
Primary antibodies were mouse anti-PPARd (1:250; Chemicon),
rabbit anti-TH (1:500; Millipore), rabbit anti-GFAP (1:100;
DAKO, Cambridgeshire, UK), rat anti-MAC-1 (1:100;
Developmental Studies Hybridoma Bank, Iowa, USA) and
rabbit anti-NeuN (1:100; Chemicon). Immunostaining was
visualised with Alexa Fluor 488 anti-mouse (1:300; Molecular
Probes, Eugene, OR) and cy-3 anti-rabbit (1:200; Jackson
Immuno Research). Immunostaining was visualised by confocal
microscopy (LSM 510, Carl Zeiss).RNA extraction and quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR)
Total RNA was extracted from selected brain regions using the
TRIzol (Invitrogen) homogenisation method as in the
manufacturer’s instructions. Samples were then subjected to a
DNase digestion, DNase I Amp Grade kit (Invitrogen), and ﬁrst
strand cDNA synthesis was carried out using the Superscript II
kit (Invitrogen). The primer sequences used in this study were
PPARd 50-TAGAAGCCATCCAGGACACC-30 (forward), 50-CC
GTCTTCTTTAGCC ACTGC-30 (reverse), b-actin as 50-TGTG
ATGGTGGGAATGGGTCAG-30 (forward) and 50-TTTGATGTC
ACGCACGATTTCC-30 (reverse). Quantitative polymerase
chain reaction ampliﬁcation was undertaken using the
Lightcycler 480 and the Lightcycler 480 SYBR green I Master
(Roche Diagnostics, Lewes, UK) as in the manufacturer’s
guidelines with an annealing temperature of 62 C for PPARd
and 67 C for b-actin. The identity of fragments ampliﬁed with
these primers was conﬁrmed by DNA sequencing performed by
DNA Sequencing & Services (College of Life Sciences,
University of Dundee, Scotland, www.dnaseq.co.uk) using
Applied Biosystems Big-Dye Ver 3.1 chemistry on an Applied
Biosystems model 3730 automated capillary DNA sequencer.Western blot analysis
Total proteins from mouse ventral midbrain, striatum and
cerebellum samples were isolated in NP-40 buﬀer (20 mM Tris–
HCl pH 8; 137 mM NaCl; 10% glycerol; 1% NP-40; 2 mM EDTA
and protease inhibitors (cOmplete Mini EDTA-free cocktail,
Roche)) 1:20 (wt/vol). Total proteins from human post-mortem
ventral midbrain and striata were isolated in NP-40 buﬀer 1:5
(wt/vol). Protein concentration was determined using a
bicinchoninic acid kit (Pierce, Rockford, IL). After boiling in
Laemmli’s buﬀer, 20 lg of protein was separated by
electrophoresis on a 10% sodium dodecyl sulphate–
polyacrylamide gel, transferred to nitrocellulose membrane, and
blocked with 5% non-fat dried milk in PBS containing 0.05%
Tween-20 (vol/vol) for 1 h. Incubation with rabbit anti-PPARd
(1:1000; Alexis Biochemicals, San Diego, CA) or mouse anti-b-
actin (1:25,000; Sigma–Aldrich) overnight at 4oC followed. Blots
were then washed in PBS–Tween (0.05%) and incubated with
either an anti-rabbit (1:5000) or anti-mouse (1:10,000)
conjugated horseradish peroxidase antibody (Amersham
Biosciences, Buckinghamshire, UK) at room temperature for
1 h. Blots were then washed in PBS–Tween (0.05%) and
developed using a chemiluminescence solution (1 ml (50 mg
luminol sodium salt (Sigma–Aldrich) in 200 ml 0.1 M Tris–HCl
pH 8.6), 100 ll (11 mg p-coumaric acid (Sigma–Aldrich) in
10 ml DMSO) and 0.3 ll 30% hydrogen peroxide). Bands were
visualised with an AlphaInnotech digital imaging system (San
Leandro, CA) and quantiﬁed with AlphaEase FC 5.02 software.Stereological counting and analysis of striatal
TH-immunoreactivity
Immunostaining for stereological counting of TH and Nissl-
stained substantia nigra pars compacta (SNpc) neurons was
carried out on midbrain sections as described in Wu et al.
(2002). Every fourth section was taken until there were 12
sections for each SNpc. The primary antibody was a polyclonal
rabbit anti-TH (1:1000; Millipore) and staining was visualised
with 3,30-diaminobenzidine (Sigma–Aldrich). The sections were
counted using regular light microscopy (AxioImager M1, Carl
Zeiss) and the optical fractionator method (West, 1993) (Stereo
Investigator version 7, MBF Bioscience, Magdeburg, Germany).
For analysis of striatal TH-immunoreactivity, every eighth
section of the striatum stained as described (Wu et al., 2002)
(rabbit anti-TH (1:500; Millipore)). TH-immunoreactivity was
assessed on scans (Hewlett Packard Scanjet G3110,
Bracknell, Berkshire, UK) of the sections using Scion Image
(Version 4.0.3.2 Scion Corporation, MD).HPLC analysis of striatal dopamine and
3,4-dihydroxyphenylacetic acid (DOPAC) levels
High-performance liquid chromatography (HPLC) with
electrochemical detection was used to measure striatal levels
of dopamine and DOPAC using a method that has been
described (Nuber et al., 2008). Brieﬂy, mice were killed 21 days
after the last MPTP injection and the striata were dissected out
and snap frozen on solid carbon dioxide. Striata were then
homogenised in 0.1 M perchloric acid (1:30 wt/vol), sonicated
and centrifuged at 18,600g at 4 C for 20 min. Following
centrifugation, 20 ll of sample was injected onto a C18 column
(Dionex, Germering, Germany) The mobile phase consisted of
90% 50 mM sodium acetate, 35 mM citric acid, 105 mg/L
octane sulfonic acid, 48 mg/L sodium EDTA solution and 10%
methanol at pH 4.3 methanol. Flow rate was 1 ml/min. Peaks
were detected by an ESA Coulchem II electrochemical detector
(ESA, Dionex) and the detector potential was set at 700 mV.
Data were collected and processed using the Chromeleon
computer system (Dionex).
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Liquid chromatography with on-line ultraviolet detection/tandem
mass spectrometry (LC–UV–MS–MS) was used to measure
striatal levels of MPP+. Brieﬂy, mice received drug treatment
as outlined in Section ‘Apoptosis assay’ and, 90 min after a
single MPTP injection (25 mg/kg), mice were sacriﬁced. The
implanted striata were dissected out and snap frozen on solid
carbon dioxide. Striata were then sonicated in 0.1 M perchloric
acid (1:30 wt/vol) and centrifuged at 14,000 rpm (18,620g;
Mikro 200R) at 4 C for 20 min. Following centrifugation, 2 ll of
sample was injected onto a Hichrom 5 l C18 column (Hichrom,
Theale, UK). The mobile phase consisted of 80% 0.1% formic
acid in water/20% 0.1% formic acid in acetonitrile. Flow rate
was 200 ll/min. MPP+ was detected by a photodiode array
detector set at 295 nm and a triple quadrupole mass
spectrometry with a mass to charge ratio of 170–128 at 32 V
and 1.9 m Torr (ThermoSurveyor PDA/TSQ Quantum,
ThermoScientiﬁc, Loughborough, UK). Data were collected and
processed using Xcalibur 2.0.7 SP1.
Statistical analysis
Data was analysed in SigmaPlot 11 for Windows (Systat
Software Inc., Chicago, IL). All values are expressed as the
mean ± SEM. Normal distribution of the data was tested and
the homogeneity of variance conﬁrmed with Levene Test. For
single pairs of data Student t-tests were used for comparisons
between means. For data sets greater that single pairs analysis
of variance (ANOVA) was used to analyse diﬀerences among
means with time, treatment, or genotype as the independent
factor, when the data were normally distributed. When ANOVA
showed signiﬁcant diﬀerences post hoc testing was used to
make comparisons between means, Dunnett’s post hoc test
was used for time-course studies and Student–Newman–Keuls
was used to make pairwise comparisons in all other studies.
Data not normally distributed were analysed with the Kruskal–
Wallis test followed by Mann–Whitney U-tests. The null
hypothesis was rejected at the 0.05 level.
RESULTS
Impacts of a PPARd agonist and antagonist in vitro
on MPP+-induced cytotoxicity
The eﬀects of the PPARd agonist GW0742 and the
antagonist GSK0660 on MPP+-induced cytotoxicity in
SH-SY5Y cells, a dopaminergic neuroblastoma cell line,
were investigated. These compounds have a high
aﬃnity for PPARd over the other PPAR isoforms,
demonstrating a selectivity of over 1000-fold for PPARd
(Table 1). Both GW0742 and GSK0660 decreased cell
viability compared to solvent-only treatment at
concentrations above 100 nM for GW0742 (p= 0.017
ANOVA, Student–Newman–Keuls post hoc test;
Fig. 1A) and above 1 lM for GSK0660 (p= 0.005
ANOVA, Student–Newman–Keuls post hoc test;
Fig. 1B). Subsequently, the impacts of theseTable 1. Activity and receptor selectivity of GW0742 and GSK0660. The activ
transactivation assay (Sznaidman et al., 2003), whilst the activity of GSK0660
et al., 2008)
PPARa PPARc
GW0742 (EC50 lM) 1.1 2
GSK0660 (IC50 lM) >10 >10compounds on MPP+-induced cytotoxicity were
assessed using maximum concentrations of 10 nM for
GW0742 and 100 nM for GSK0660. The cytotoxicity of
MPP+ was unaﬀected by treatment with GW0742, but
was increased in the presence of 100 nM GSK0660 as
measured by a reduction in cell viability compared to
MPP+ alone (p= 0.008 ANOVA, Student–Newman–
Keuls post hoc test; Fig. 1C). This increase in toxicity
was reduced by pre-treatment with GW0742 and
subsequent co-treatment with GSK0660, and was
therefore due to a pharmacological eﬀect of GSK0660,
and not due to any synergistic toxic eﬀects with MPP+.
Co-treatment following GSK0660 pre-treatment did not
aﬀect the increase in toxicity compared to MPP+ alone.
Despite these alterations in cell viability neither 100 nM
GSK0660, 10 nM GW0742 or the co-treatments had any
eﬀects on MPP+-induced cytotoxicity as measured by
LDH release (Fig. 1D), suggesting that inhibition of
PPARd may aﬀect cellular metabolic status, altering
MTT conversion to its insoluble formazan, although this
does not lead to an alteration in cell death in this model.
Apoptotic cell counts using the same treatment
regimen in primary dopaminergic neurons showed that
co-treatments with either GW0742 and/or GSK0660 had
no eﬀect on MPP+-induced cytotoxicity (Fig. 2A) as
determined by apoptotic cell counts. Although not
signiﬁcant, GW0742 showed a tendency to protect
against MPP+-induced toxicity and ameliorate the
additive eﬀects of GSK0660 on MPP+-induced toxicity.Eﬀects of MPTP treatment on PPARd expression
in vivo
Having ascertained that inhibition of PPARd activation
impacts on MPP+ cytotoxicity in a cell culture
model of PD the next step was to determine the
immunohistological localisation of PPARd in vivo. This
was examined by ﬂuorescent double-labelling using TH
as a marker for dopaminergic cells, GFAP as a marker
for astrocytes, MAC-1 as a marker for microglia and
NeuN as a general neuronal marker two days after
MPTP treatment. PPARd is widely expressed in
neuronal nuclei in both the SNpc and the striatum
(Fig. 3A i–iii and B i–iii), including the nuclei of TH-
positive cells in the SNpc (Fig. 3A iv–vi and xiii). PPARd
also co-localised with GFAP, indicating expression in
astrocytes in both the SNpc and the striatum (Fig. 3A
viii–ix and B iv–vi). No expression of PPARd was
detected in microglia (Fig. 3A x–xii and B vii–ix).
Following this conﬁrmation that PPARd is expressed in
the SNpc and striatum, the impact of MPTP treatment
on PPARd levels was determined. Quantitative PCR
showed a signiﬁcant increase in PPARd mRNA in theity of GW0742 is expressed as the EC50 (lM) for this compound in a
is expressed as the IC50 (lM) in a GAL4 LBD chimera assay (Shearer
PPARd Selectivity for PPARd
0.001 >1000-fold
0.155 >1000-fold
Fig. 1. Eﬀects of the PPARd agonist GW0742 and the antagonist GSK0660 on MPP+ cytotoxicity as measured by cell viability and LDH release.
The impact of GW0742 (A) and GSK0660 (B) on cell viability was assessed by MTT reduction. Concentrations of GW0742 above 10 nM and
concentrations of GSK0660 above 100 nM decreased cell viability compared to control (0.1% DMSO). GSK0660 (100 nM) and GSK0660 pre-
treatment followed by co-treatment with GW0742 (10 nM) increased the MPP+-induced decrease in cell viability compared to MPP+ alone (C). This
was reversed by pre-treatment with GW0742 (10 nM) and then co-treatment. Neither GW0742 nor GSK0660 aﬀected MPP+ induced LDH release
(D). Data are mean ± SEM, n= 3, #p< 0.05 MPP+ compared to control; ⁄p< 0.05; ⁄⁄p< 0.01 compared to MPP+ alone, GW0742 pre-
treatment compared to GSK0660 pre-treatment (ANOVA followed by Student–Newman–Keuls post hoc test).
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after MPTP administration compared to saline-treated
mice (p< 0.001 ANOVA, Dunnett’s post hoc test;
Fig. 3C) when normalised to b-actin levels (b-actin
levels were unchanged by MPTP treatment, data notshown). PPARd mRNA levels were also transiently
increased in the striatum, where the dopaminergic
neurons of the SNpc terminate. In contrast to the ventral
midbrain, this increase was immediately after MPTP
treatment (p= 0.011 ANOVA, Dunnett’s post hoc test;
Fig. 2. Eﬀect of the PPARd agonist GW0742 and antagonist GSK0660 on apoptosis in rat ventral midbrain dopaminergic cells. MPP+ (20 lm)
administration caused an increase in cellular apoptosis as compared to control (0.1% DMSO) cells. Addition of 100 nM GSK0660 exacerbated this
eﬀect. No eﬀect was evident with GW0742 administration or co-treatments (A). Nuclear (blue) co-localisation of PPARd (red) in ventral midbrain
dopaminergic cells (B). Imaging of MPP+-treated cells, blue nuclear staining with Hoechst 33258 and red TH-immunoreactivity (C). Apoptotic cells
were identiﬁed by nuclear condensation and/or fragmentation (D). Data are mean ± SEM. All treatments were performed in triplicate and the
average taken from four independent experiments. The results were compared by one-way ANOVA and Newman–Keuls post hoc test. ⁄p< 0.05
compared to control. (TH – tyrosine hydroxylase) Scale bars = 20 lm. (For interpretation of the references to colour in this ﬁgure legend, the reader
is referred to the web version of this article.)
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changes at the protein level. Interestingly, levels of
PPARd protein in the ventral midbrain were unaﬀected
by MPTP treatment (Fig. 3E), as was the case for
cerebellum, a control tissue (data not shown). In the
striatum, the level of PPARd protein was signiﬁcantly
increased immediately after MPTP treatment (p< 0.001
ANOVA, Dunnett’s post hoc test; Fig. 3F), which
correlated with the increase in PPARd mRNA levels.Genetic manipulation of PPARd levels does not alter
MPTP toxicity
Having established that PPARd levels are altered by
MPTP treatment and that GSK0660 increased MPP+
cytotoxicity in vitro, the eﬀects of reducing PPARd levels
in vivo on MPTP toxicity were explored. Due to the low
bioavailability of GSK0660 (Shearer et al., 2008), agenetic approach was attempted, however, mice
homozygous-null for PPARd are not viable due to
ectoplacental defects (Barak et al., 2002; Wang et al.,
2007). A comparison of PPARd mRNA levels in
untreated heterozygous mice and their wild-type
littermates was undertaken to ensure signiﬁcant
reductions in PPARd expression. PPARd mRNA in
heterozygous mice was reduced by approximately 70%
(p= 0.003 Student t-test; Fig. 4A). The response of
heterozygous mice and their wild-type littermates to
MPTP was then assessed and there were no
diﬀerences in their sensitivity to MPTP-induced
neuron loss (Fig. 4B–D). MPTP reduced both TH-
positive and Nissl-positive neuron numbers when
compared to saline-treated mice of the appropriate
genotype (p< 0.001 ANOVA with Student–Newman–
Keuls post hoc test). Striatal TH-immunoreactivity was
also assessed for diﬀerences between wild-type and
Fig. 3. PPARd immunolocalisation and alterations in PPARd expression following MPTP treatment. Double immunoﬂuorescence conﬁrms that
2 days after MPTP treatment PPARd (green) is expressed in neuronal nuclei in the substantia nigra (A) and striatum (B) labelled with NeuN (i–iii;
red), including in TH-positive neurons ((A) iv–vi and xiii; red), and in GFAP-positive astrocytes ((A) vii–ix and (B) iv–vi; red). PPARd was not
expressed in MAC-1-positive microglia ((A) x–xii and (B) vii–ix; red). PPARd mRNA levels in the ventral midbrain are increased 7 days after MPTP
compared to saline-treated mice (A), but no alterations in PPARd protein levels are seen in this region after MPTP (B). In the striatum mRNA (C) and
protein (D) PPARd levels are increased immediately after MPTP before returning to basal levels. PPARd protein levels are unchanged in the
cerebellum after MPTP treatment (E). Data are mean ± SEM, n= 3–6 mice per timepoint. ⁄⁄p< 0.01, ⁄⁄⁄p< 0.001 compared to saline (ANOVA
with Dunnett’s post hoc test) (d – days after MPTP (5  30 mg/kg) administration) (TH – tyrosine hydroxylase; GFAP – glial ﬁbrillary acidic protein;
MAC-1 – macrophage antigen complex-1). Scale bars = 20 lm. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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Fig. 4. Eﬀects of genetic manipulation of PPARd levels on MPTP neurotoxicity. PPARd heterozygous mice have reduced PPARd mRNA levels
compared to their wild-type littermates (A). No diﬀerence is seen between wild-type mice and their heterozygous littermates (null mice were not
viable) in their sensitivity to MPTP toxicity. Representative micrographs of TH- and Nissl-stained sections (B) (Scale bar = 200 lm). Both TH-
positive neuron (C) and Nissl-positive neuron (D) numbers were reduced by MPTP in wild-type and heterozygous mice. No diﬀerences were
detected in striatal TH-immunoreactivity (E and F) between wild-type and heterozygous mice. PPARd protein levels in untreated mice were not
signiﬁcantly diﬀerent between heterozygous mice and their wild-type littermates (G). Data are mean ± SEM, n= 6–7 mice per group for
stereological counting and n= 3 mice per group for mRNA and protein analysis. ⁄⁄p< 0.01; ⁄⁄⁄p< 0.001 (Student t-test (A) or ANOVA with
Student–Newman–Keuls post hoc test) (WT – wild-type; Het – heterozygous; TH – tyrosine hydroxylase; SNpc – substantia nigra pars compacta).
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Table 2. Eﬀects of genetic manipulation of PPARd levels on striatal dopamine and DOPAC levels. No diﬀerence is seen between wild-type mice and
their heterozygous littermates (null mice were not viable) in their sensitivity to MPTP toxicity as measured by reduction in dopamine and DOPAC levels.
Data are mean ± SEM, n= 7 mice per group. ⁄⁄⁄p< 0.001 compared to appropriate saline-treated group (Kruskal–Wallis test with Mann–Whitney U-
post hoc tests; WT – wild-type, Het – heterozygous)
Saline MPTP
WT Het WT Het
Dopamine (ng/mg wet tissue) 15.98 ± 1.87 19.06 ± 2.05 2.67 ± 0.44⁄⁄⁄ 1.73 ± 0.34⁄⁄⁄
DOPAC (ng/mg wet tissue) 2.07 ± 0.32 1.85 ± 0.60 0.50 ± 0.06⁄⁄⁄ 1.12 ± 0.42
Table 3. Eﬀects of intra-striatal infusion of GW0742 on striatal dopamine and DOPAC levels. No diﬀerence is seen in MPTP-induced reductions in
dopamine and DOPAC levels between mice infused with GW0742 or those receiving vehicle (25% DMF in PBS – see Experimental procedures for
details). Data are mean ± SEM, n= 3–5 mice per group. ⁄p< 0.05 0; ⁄⁄p< 0.01 compared to appropriate saline-treated group (Kruskal–Wallis test
with Mann–Whitney U-post hoc tests)
Saline MPTP
Vehicle GW0742 Vehicle GW0742
Dopamine (ng/mg wet tissue) 12.30 ± 1.69 10.82 ± 2.12 3.57 ± 0.43⁄⁄ 3.53 ± 0.68⁄⁄
DOPAC (ng/mg wet tissue) 1.38 ± 0.18 1.32 ± 0.35 0.79 ± 0.06⁄ 0.63 ± 0.12
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although no diﬀerences were observed (Fig. 4E, F). The
levels of dopamine and DOPAC, a major metabolite of
dopamine, in the striatum were reduced by MPTP
treatment in both wild-type and heterozygous mice, as
measured by HPLC (p< 0.001 Kruskal–Wallis test with
Mann–Whitney U-post hoc tests; Table 2) Following the
lack of impact of genetic manipulation on MPTP toxicity,
the levels of PPARd protein between wild-type and
heterozygous mice were examined in untreated mice. In
contrast to PPARd mRNA levels, there was no
signiﬁcant reduction in PPARd protein in heterozygous
mice compared to their wild-type littermates (Fig. 4G),
which may underlie the lack of alteration in sensitivity to
MPTP treatment in these mice.Treatment with the PPARd agonist GW0742 provides
neuroprotection against MPTP toxicity
The data from the PPARd heterozygous mice were not
deﬁnitive, as these mice had the same expression level
of PPARd protein as their wild-type littermates.
Subsequently, pharmacological modulation of PPARd
with intra-striatal infusion of the agonist GW0742 was
undertaken, as this had reversed the eﬀects of
GSK0660 in vitro. Infusion of GW0742 into the striatum
was chosen since this was the region where consistent
alterations in PPARd levels following MPTP treatment
were observed. GW0742 infusion did not aﬀect MPTP-
induced decreases in dopamine and its metabolites in
the striatum (Table 3). However, GW0742 infusion did
reduce MPTP-induced decreases in TH-positive and
Nissl-positive neuron numbers in the SNpc compared to
mice infused with vehicle only (TH p= 0.044 ANOVA,
Student–Newman–Keuls post hoc test; Nissl p= 0.036
Kruskal–Wallis test with Mann–Whitney U-post hoc
tests; Fig. 5). This protection was not due to alterations
in MPTP bioactivation to MPP+ as striatal levels of
MPP+ were greater in the mice receiving GW0742 than
in the mice receiving vehicle only (Table 4).Human Parkinson’s disease patients show no
changes in PPARd levels
To investigate possible changes in PPARd levels in PD,
its expression in post-mortem tissue from PD patients
was assessed. Firstly, the localisation of PPARd in the
SNpc of PD patients was established. PPARd was
consistently expressed in TH-positive neurons within the
SNpc, correlating with the ﬁndings in SH-SY5Y cells and
those in mice (Fig. 6A). Having determined that PPARd
was expressed in PD patients, Western blot analysis
was performed to ascertain whether any alterations in
PPARd protein levels could be detected compared to
control tissue. No alterations in PPARd protein levels
were observed between the ventral midbrains of PD
patients and controls (Fig. 6B), consistent with the
results from the mouse study. PPARd protein was not
detected in the striatum of either PD patients or controls.DISCUSSION
This study sought to determine the role of PPARd in
MPTP toxicity, as activation of the other PPAR isoforms
show neuroprotective eﬀects (Breidert et al., 2002;
Dehmer et al., 2004; Kreisler et al., 2007; Schintu et al.,
2009; Martin et al., 2012). Intra-striatal infusion of
GW0742 was neuroprotective in vivo against MPTP-
induced dopaminergic neuron loss. This protective eﬀect
of GW0742 did not extend into the striatum despite this
being the region where consistent changes in PPARd
levels were seen. This is in contrast to the work of
Iwashita et al. (2007), who saw an attenuation of the
MPTP-induced decreases in striatal dopamine and
DOPAC levels following intra-cerebral ventricular
infusion with two other PPARd agonists, L-165041 and
GW501516. The eﬀects on dopaminergic neuron
number were not assessed. The diﬀerences between
the work of Iwashita et al. (2007) and this study may
arise from variations in the MPTP regimes, infusion site
and doses of agonist used. Indeed the protective eﬀects
Fig. 5. Eﬀects of intra-striatal infusion of the PPARd agonist GW0742 on MPTP neurotoxicity. (A) Representative micrographs of TH and Nissl-
stained sections following infusion with GW0742 or vehicle (25% DMF in PBS) (Scale bar = 200 lm). Infusion of GW0742 reduced MPTP-induced
loss of TH-positive (B) and Nissl-positive (C) neurons compared to infusion of vehicle. Data are mean ± SEM, n= 3–5 mice per group. ⁄p< 0.05
(ANOVA with Student–Newman–Keuls post hoc test; Nissl – Kruskal–Wallis test with Mann–Whitney U-post hoc test) (TH – tyrosine hydroxylase;
SNpc – substantia nigra pars compacta).
Table 4. Eﬀects of intra-striatal infusion of GW0742 on striatal levels of
MPP+. No diﬀerences were seen in striatal levels of MPP+ between
mice infused with GW0742 or those receiving vehicle (25% DMF in
PBS). Data are mean ± SEM, n= 2–5 mice per group
Vehicle GW0742
MPP+ (lg/g wet tissue) 11.54 ± 1.46 7.53 ± 1.39
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120 lg/day, which is higher than the dose used in this
study (84 lg/day).
The neuroprotective eﬀects of GW0742 were not seen
in vitro in SH-SY5Y cells, although treatment with
GW0742 attenuated the detrimental eﬀects of GSK0660
treatment on MPP+-cytotoxicity. It is likely that thesediscrepancies are the result of PPARd being expressed
in both astrocytes and neurons in vivo compared with
neuronal cells only in vitro. Indeed, PPARd expression
after MPTP treatment was upregulated in the striatum in
a time-frame that was compatible with that of
astrogliosis (Ciesielska et al., 2009). Astrocytes,
together with microglia, are an important source of both
pro- and anti-inﬂammatory mediators including TNFa,
IL-6 and IL-10 (Dong and Benveniste, 2001; Long-Smith
et al., 2009), and the other PPAR isoforms are
documented to have anti-inﬂammatory eﬀects.
Moreover, agonists of both PPARa and PPARc are
known to reduce nitric oxide and pro-inﬂammatory
cytokine release from activated microglia and astrocytes
(Dehmer et al., 2004; Santos et al., 2005; Storer et al.,
2005; Xu et al., 2006; Nicolakakis et al., 2008; Yi et al.,
2008; Escribano et al., 2009). These anti-inﬂammatory
Fig. 6. PPARd in human post-mortem tissue. Double immunoﬂuor-
scence conﬁrms that PPARd (green) is expressed in dopaminergic
neurons (TH-positive; red) in the substantia nigra ((A) i–iii). No
diﬀerence in PPARd protein level in the ventral midbrain is seen
between PD patients and controls (B). Open triangle is mean ± SEM
for control; Closed triangle is mean ± SEM for PD patients; n= 4–6.
(PD – Parkinson’s disease; TH – tyrosine hydroxylase) Scale
bars = 50 lm. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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eﬀects of PPARa and PPARc agonists against MPTP
toxicity (Breidert et al., 2002; Dehmer et al., 2004;
Kreisler et al., 2007; Schintu et al., 2009). Therefore it is
possible that the protective eﬀects of GW0742 are
mediated by anti-inﬂammatory mechanisms potentially
focussed on astrocytes, as no expression of PPARd
was detected in microglia. This is supported by the lack
of eﬀect of GW0742 against MPP+ toxicity in vitro.
Whether these anti-inﬂammatory actions are direct or
result from the release of transcriptional repression of
the other PPAR isoforms is not clear, as non-liganded
PPARd inhibits the ligand-induced transcriptional activity
of other PPAR isoforms (Shi et al., 2002). Further
exploration of the eﬀects of PPARd agonists in vivo
should seek to clarify if the protective eﬀects of
GW0742 are PPARd-dependent and if these eﬀects are
mediated by an alteration of the inﬂammatory responses
generated by MPTP treatment.In vitro data where GSK0660 reduced cell viability, an
eﬀect reversed upon co-treatment with GW0742, suggest
that a degree of basal activity of PPARd is required to
maintain neuronal cell viability. Indeed, GSK0660 has
been reported to act as an inverse agonist when
administered alone (Shearer et al., 2008) and PPARd is
important in cellular metabolic pathways (Basu-Modak
et al., 1999; Luquet et al., 2005). This is further
supported by the maintenance of wild-type levels of
PPARd protein seen in PPARd heterozygous mice, even
though these mice had approximately half the level of
PPARd mRNA compared to their wild-type littermates.
This type of discrepancy between mRNA and protein
levels has been reported in mice heterozygous for other
genes (Chen et al., 1997; Takahashi et al., 2002), and
could be expected if PPARd has a signiﬁcant and
necessary function in the basal activity in neurons. The
nature of this potential basal activity is currently unclear.
In the ventral midbrain only PPARd mRNA levels were
upregulated. The lack of a concurrent protein upregulation
is not unusual, as increases in mRNA levels do not always
correlate with increases in protein levels (Chen et al.,
2002; Pascal et al., 2008) and activation of mouse liver
PPARa and PPARc with Wy-14643 and rosiglitazone,
respectively, only gave a 40% correlation between
changes in mRNA and protein levels (Tian et al., 2004).
The lack of alteration in PPARd protein levels in the
ventral midbrain was reﬂected in human post-mortem
tissue when compared to control tissue, suggesting that
there may be a degree of correlation between the
mouse model and the clinical situation. Unfortunately,
PPARd protein was not detected in the human striatal
extracts and, to the authors’ knowledge, PPARd has not
yet been detected in human striatum elsewhere in the
literature. Species diﬀerences in PPARd expression
between human and rodent tissues have been reported
in urothelium and intrafollicular epidermal cells (Chopra
et al., 2008; Yacoub et al., 2008). This means that the
degree of correlation between PPARd expression in
MPTP toxicity and in PD pathogenesis remains unclear.
However, changes between PD patients and control
tissue may not have been seen since PPARd levels
were only transiently increased in mouse striatum
immediately after MPTP, while the human post-mortem
samples represent a later stage of disease progression.CONCLUSION
This study shows that GW0742 provides neuroprotective
eﬀects in a mouse model of PD, which supports ﬁndings
from other neurodegenerative diseases including
multiple sclerosis and Alzheimer’s disease (Polak et al.,
2005; Kalinin et al., 2009). As the precise functions of
PPARd in neurons and astrocytes have not been
delineated, the cellular mechanisms underlying these
protective eﬀects remain unclear. The importance of the
PPARd basal activity suggested by the in vitro work
indicates that the protective eﬀects of GW0742 may
arise from the maintenance of cellular metabolic status.
Alternatively, the presence of PPARd in astrocytes and
the in vivo protective eﬀects of GW0742 support an
202 H. L. Martin et al. / Neuroscience 240 (2013) 191–203anti-inﬂammatory role for this ligand-activated tran-
scription factor. It is possible that PPARd agonism is
neuroprotective via multiple modes of action and further
work will be required to delineate the importance of
each of these mechanisms to the neuroprotection
aﬀorded by PPARd agonists.DISCLOSURE STATEMENT
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